DBV Technologies S.a. cash flow statement
In fiscal 2025, DBV Technologies S.a.'s operations generated −$121m of cash; it spent $532,000 on capital projects, leaving free cash flow of −$122m.
Cash flow statement
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −148 | −166 | −108 | −56 | −80 | −104 | −121 | −188 |
| Depreciation and amortisation | — | 4 | 4 | 3 | 4 | 3 | 3 | — |
| Stock-based pay | 17 | −1 | 3 | 5 | 6 | 5 | 5 | 13 |
| Capital spending | 6 | 3 | 1 | 1 | 1 | 2 | 1 | 3 |
| Free cash flow | −154 | −168 | −109 | −56 | −80 | −107 | −122 | −192 |
| Free cash flow after stock pay | −171 | −167 | −112 | −61 | −86 | −111 | −127 | −205 |
| Shares issued | 209 | 150 | 150 | 194 | 7 | 1 | 276 | 296 |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −12 | −20 | −34 | −32 | −35 | −49 | −53 | −52 |
| Depreciation and amortisation | — | — | — | — | — | — | — | 1 |
| Stock-based pay | −0 | 2 | 1 | 1 | 2 | 2 | 4 | 5 |
| Capital spending | −0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Free cash flow | −12 | −20 | −34 | −33 | −36 | −50 | −53 | −54 |
| Free cash flow after stock pay | −12 | −21 | −35 | −33 | −37 | −52 | −57 | −59 |
| Shares issued | 1 | 0 | 117 | 0 | 159 | 89 | −0 | 48 |
Compare with peers
- Dyadic International Inc cash flow
- Aligos Therapeutics, Inc. cash flow
- Camp4 Therapeutics Corp cash flow
- Curis Inc cash flow
- Ensysce Biosciences, Inc. cash flow
Head to head: DBVT vs DYAIALGS vs DBVTCAMP vs DBVT
More: Biotechnology stocks compared, Health Care sector, rankings of US companies